Major focus is on the development of novel biologics for cancer and infectious disease. For more than 27 years, Amgen scientists have applied innovative research to advance important new therapies for grievous illnesses. Amgen’s heritage lies in leading-edge molecular biology. This basic science platform permitted the development of protein therapeutics that have transformed the management of anaemia, inflammation, and cancer.
More recently, Amgen has assembled a multidisciplinary group of chemists and biologists who, together, approach the challenge of drug discovery using multiple potential therapeutic modalities. The research program that was started 27 years ago has grown spectacularly, yielding a heightened understanding of human disease, and innovative new approaches to improving human health.